-
SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018): MSK-IMPACT sequencing of 86 patients with HER2- and HER3-mutant cancers
- Description
This dataset contains summary data visualizations and clinical data from a broad sampling of HER2- and HER3-mutant tumors. The data was generated utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, Amplification Status, Best objective response rate, Bubble...
- Subject
-
Breast NeoplasmsCarcinoma, HepatocellularCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellColorectal NeoplasmsDNA Mutational AnalysisEndometrial NeoplasmsEsophageal NeoplasmsGenes, erbBGenes, erbB-2MelanomaOvarian NeoplasmsPancreatic NeoplasmsSalivary Gland NeoplasmsSarcomaSkin NeoplasmsUrinary Bladder NeoplasmsUterine Cervical Neoplasms
- Access Rights
- Free to All
-
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
- Authors
- Burman, BharatJain, SwatiFitzgerald, Conall W.R.Sherman, Eric J.22 more author(s)...
- Description
Description from Zenodo: "This is a de-identified dataset accompanying the Nature Medicine publication titled "Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial", by Vos et al. (DOI: https://doi.org/10.1038/s41591-023-02518-x). It contains the clinical features and processed data of 64 patients with salivary gland cancer, treated with nivolumab and ipilimumab immunotherapy....
- Subject
-
Clinical Trial, Phase IIImmunotherapyIpilimumabNivolumabSalivary Gland Neoplasms
- Access Rights
- Free to All
-
Determinants of Response to Nivolumab plus Ipilimumab in a Phase II Trial of Advanced Salivary Gland Cancer Patients
- Description
Description from BioProject: "Salivary gland cancers (SGCs) are rare, aggressive cancers that lack effective treatments in the metastatic setting. We report the clinical results and immunogenomic correlates of response from a phase II trial evaluating nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) in metastatic SGC patients."
- Subject
-
Clinical Trial, Phase IIExome SequencingIpilimumabNivolumabRNA-SeqSalivary Gland Neoplasms
- Access Rights
- Free to All